LIFERIVER(SH:688317) Zhong Guo Jing Ji Wang·2025-10-22 02:36Core Points - The company reported a significant decline in revenue and net profit for the first half of 2025, with a revenue of 59.68 million yuan, down 36.91% year-on-year, and a net profit attributable to shareholders of -9.85 million yuan [1] - The company has projected net losses of 137 million yuan and 127 million yuan for the years 2023 and 2024, respectively [2] Financial Performance - In the first half of 2025, the company achieved a net cash flow from operating activities of 25.82 million yuan [1] - The net profit after deducting non-recurring gains and losses for the first half of 2025 was -13.25 million yuan [1] IPO and Stock Performance - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 18, 2021, with an initial issuance of 48,676,088 shares at a price of 43.22 yuan per share [3] - The stock price peaked at 93.80 yuan within six trading days after the IPO but has since experienced a downward trend, currently trading below the IPO price [3] - The total funds raised during the IPO amounted to 2.10 billion yuan, with a net amount of 1.94 billion yuan, exceeding the original plan by 586.43 million yuan [3] Use of IPO Proceeds - The funds raised are intended for projects including the upgrade of production lines, the establishment of a molecular diagnostics research center, marketing and service network upgrades, product development, and to supplement working capital [4]